A Phase 4 interventional study of Alprostadil and Nitroglycerin in ST Segment Elevation Myocardial Infarction and Coronary Slow Flow Phenomenon, sponsored by RenJi Hospital. Completed at 1 site in China. Per ClinicalTrials.gov, last updated 2020-03-12.
Sponsored by RenJi Hospital · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in ST Elevation Myocardial Infarction by RenJi Hospital — 2 open to participants now, 2 under way, none of them phase 3. ST Elevation Myocardial Infarction · RenJi Hospital.
Among the 13 studies in ST Elevation Myocardial Infarction by RenJi Hospital, this one is one of 2 that started in 2015, is one of 4 in phase 4, and was the 3rd registered.
854 studies on the registry are indexed under ST Elevation Myocardial Infarction; 200 are open to participants now.
Browse ST Elevation Myocardial Infarction studies →2 of the 13 studies in ST Elevation Myocardial Infarction by RenJi Hospital are open now, in 1 country. Recruiting first, the newest first:
RenJi Hospital · Sites in China
Ages 17–75
RenJi Hospital · Sites in China
Ages 18+
By country, each count listing its studies:
Of the 122 ST Elevation Myocardial Infarction studies recruiting now, 76 (62%) set no upper age limit and 20 (16%) stop at 75 or younger; 10 take children under 18; 9 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 57 is below the median of 193 across 530 interventional studies indexed under ST Elevation Myocardial Infarction.
Median enrollment 280 across the 9 interventional studies, 522 across the 4 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
RenJi Hospital is the lead sponsor of 551 studies on the registry; 248 are open to participants now.
1 of the studies in ST Elevation Myocardial Infarction by RenJi Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05967663RenJi HospitalFractional Flow Reserve Guided Immediate Versus Staged Complete Myocardial Revascularization in Patients With ST-segment Elevation Myocardial Infarction With Multivessel Disease (Future Study) | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in ST Elevation Myocardial Infarction by RenJi Hospital, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study intends to evaluate the efficacy of different medicine delivering by targeted perfusion catheter in coronary administration on coronary blood flow in STEMI patients with CSFP.
The goal of STEMI therapy is to successfully restore epicardial blood flow. PCI has been documented as being the most effective method for restoration of epicardial blood flow. However, stenting does not necessarily equate to epicardial blood flow; not every patient achieves TIMI 3 flow after successful PCI.
Currently, there are two main types of interventions to improve epicardial blood flow. One is the mechanical method, which included thrombus aspiration catheter and the distal protective devices. It has been confirmed that the mechanical method can effectively improve epicardial and myocardial perfusion in patient with part of large vessels and high burden thrombus. But for patients with small vessels and no obvious visual thrombus, the efficacy is not significant.
The other intervention is medicine which included GP IIb/IIIa receptor antagonist, adenosine, sodium nitroprusside, verapamil etc. Part of the drugs have some effect but the overall clinical efficacy is still not satisfied.
The study intends to use targeted perfusion catheter to deliver drug to the distal targeted blood vessels. TFG and cTFC are applied to evaluate the efficacy of treatment with Alprostadil or Nitroglycerin on coronary blood flow in STEMI patients with CSFP.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patents with myocardial infarction who have symptom onset within 12h before randomization; : ≥2 mm ST-segment elevation in 2 contiguous precordial leads or ≥1 mm ST-segment elevation in 2 contiguous extremity leads ; Corrected TIMI frame counted (cTFC) measured from the final angiographic imaging after PCI exceeding 40 frames; Signed form prior to trial participation.
Exclusion Criteria:
Coronary artery bypass surgery (CABG) history; Failed in stents implanting; Severe heart failure; Cardiogenic shock.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
alprostadil,2ug, delivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients with CSFP
Drug: Alprostadil
nitroglycerin,200ug, delivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients with CSFP
Drug: Nitroglycerin
alprostadil,2ug, delivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients with CSFP
Nitroglycerin,200ug, delivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients with CSFP
TIMI Flow Grade (TFG)
TIMI Flow Grade (TFG)assesses flow in the epicardial arteries
Time frame: One mins after PCI
TIMI Flow Grade (TFG)
TIMI Flow Grade (TFG)assesses flow in the epicardial arteries
Time frame: One mins after intracoronary medicine infusion post-PCI
TIMI Frame Count (CTFC)
CTFC is a continuous measurement assessing flow in the epicardial arteries.
Time frame: One mins after PCI
TIMI Frame Count (CTFC)
CTFC is a continuous measurement assessing flow in the epicardial arteries.
Time frame: One mins after intracoronary medicine infusion post-PCI
LVEF by echocardiography
Echocardiographic index includes LVEF
Time frame: Echocardiography was performed 3-7 days after PCI
Ran from Aug 2015 to primary completion in Apr 2017, 20 months.
Of 44 non-industry phase 4 interventional studies under ST Elevation Myocardial Infarction, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 74. This study's 20 months is below that.
Counting every sponsor, half of 49 studies reached it within 34 months; a quarter within 22 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alprostadil
ST Elevation Myocardial Infarction →